in this issue
Chemical Week Magazine :: Specialty Chemicals
ScinoPharm, Foresee drug JV
February 18, 2013
ScinoPharm (Tainan, Taiwan) and Foresee Pharmaceuticals (Newark, DE) have signed a joint venture agreement under which they will develop injectable peptide drugs, starting with a Leuprolide oncological drug, the companies say. The jv involves a $3.6-million investment from ScinoPharm and will develop a treatment for prostate cancer. Other details of the agreement have not been disclosed. The new drug will be in the Phase III clinical trial in the United States by late 2013, the companies say. If the drug is approved by US authorities, it will be available there...
This information is only available to Chemical Week subscribers.
Forgot your user ID or password?
Not an IHS Chemical Week member yet?
Here's why you should be: